DISTILLATION №78 · ALEMBIC LABS

HUMANIN — DOUBLE SUBSTITUTION ASP-10 (NATIVE VIA L-ASP AT POSITION 10? NOTE NATIVE IS LEU-10; INTRODUCE L10D) AND SER-14 → L-2,4-DIAMINOBUTYRIC ACID (DAB), THEN FORM AN INTRAMOLECULAR SIDE-CHAIN-TO-SIDE-CHAIN LACTAM BRIDGE BETWEEN THE ASP-10 Β-CARBOXYLATE AND THE DAB-14 Γ-AMINE, CREATING A COVALENT I,I+4 AMIDE STAPLE ACROSS ONE HELICAL TURN IN THE CENTRAL BAX-ENGAGING SEGMENT. NATIVE CYS-8 IS PRESERVED FREE.

generated 2026-05-05T01:59:07.540527+00:00

DISCARDED LONGEVITY

DOUBLE SUBSTITUTION ASP-10 (NATIVE VIA L-ASP AT POSITION 10? NOTE NATIVE IS LEU-10; INTRODUCE L10D) AND SER-14 → L-2,4-DIAMINOBUTYRIC ACID (DAB), THEN FORM AN INTRAMOLECULAR SIDE-CHAIN-TO-SIDE-CHAIN LACTAM BRIDGE BETWEEN THE ASP-10 Β-CARBOXYLATE AND THE DAB-14 Γ-AMINE, CREATING A COVALENT I,I+4 AMIDE STAPLE ACROSS ONE HELICAL TURN IN THE CENTRAL BAX-ENGAGING SEGMENT. NATIVE CYS-8 IS PRESERVED FREE.

APOPTOSIS REGULATOR BAX

AVERAGE CONFIDENCE	PTM / IPTM	VERDICT
43.9%	0.347 / 0.118	DISCARDED
TARGET	**UNIPROT**	**BINDING PROBABILITY**
Apoptosis regulator BAX	Q07812	—

TLDR

FOLD №78 attempted to model a lactam-stapled Humanin variant — introducing L10D and S14Dab modifications to form an i,i+4 covalent amide bridge across the central BAX-engaging helix — but was DISCARDED due to a structural prediction failure, not biological invalidation. The fold achieved a pLDDT of 0.44 and an ipTM of 0.12, values too low to interpret binding geometry, helical register, or interface quality. This represents a tool-limit outcome: the current prediction pipeline cannot reliably model non-canonical amino acids like Dab or the crosslinked lactam geometry with sufficient confidence. The scientific hypothesis — that an irreversible, redox-stable amide staple would outperform the PROMISING disulfide staples from Folds #22 and #66 — remains untested rather than disproved.

EXECUTIVE SUMMARY

FOLD №78 — Humanin lactam staple (L10D/S14Dab, i,i+4) — DISCARDED: pLDDT 0.44, ipTM 0.12. Tool-limit failure; non-canonical Dab residue and covalent crosslink are outside the predictor's vocabulary. The redox-stable staple hypothesis remains open — not disproved.

DETAILED ANALYSIS

Humanin (HN) is a 24-residue mitochondrial-derived peptide with well-characterized anti-apoptotic activity. Its primary molecular mechanism involves direct physical binding to BAX, the pro-apoptotic BCL-2 family effector, preventing BAX's cytosol-to-mitochondria translocation and mitochondrial outer-membrane permeabilization (MOMP). Guo et al. (2003) demonstrated nanomolar-range inhibition of BAX membrane association in cell-free systems, and Morris et al. (2019) showed that HN and BAX co-assemble into fibers that sequester BAX — a conformation-sensitive process in which HN point mutations that alter anti-apoptotic activity also alter fiber morphology. This makes HN's three-dimensional structure directly pharmacologically relevant.

The Alembic lab has now run four Humanin folds exploring helical stabilization strategies. Folds #22 and #66 both installed disulfide staples — an i,i+6 Cys-8/Cys-14 bridge and an i,i+4 Cys-7/Cys-11 bridge, respectively — and both returned PROMISING verdicts with pLDDT scores of 0.56. These results established that helical pre-organization is a productive direction for Humanin optimization and that the pipeline can model linear-backbone Humanin with moderate confidence when the only modifications are canonical cysteine substitutions forming a disulfide. Fold #37 (S7A) returned a DISCARDED verdict at pLDDT 0.62 — higher confidence geometrically but not a productive binding prediction. Fold #59 (N-terminal myristoylation) FAILED entirely due to the lipid modification.

Fold #78 represented a logical next step in the stapling series: replacing the redox-sensitive disulfide with a chemically irreversible lactam bridge. The specific chemistry — introducing Asp at position 10 (native Leu) and the non-canonical L-2,4-diaminobutyric acid (Dab) at position 14 (native Ser), then cyclizing via an amide bond between the Asp β-carboxylate and the Dab γ-amine — creates a covalent i,i+4 amide staple. This class of staple is well-precedented in the α-helical peptide literature (Felix, Houston; SAHB analogs of BH3 peptides) and is chemically stable under the reducing conditions of the cytosol where BAX resides, directly addressing the principal theoretical limitation of the Cys-based staples.

However, the structural prediction pipeline returned a pLDDT of 0.44, a pTM of 0.35, and an ipTM of 0.12 — all substantially below interpretable thresholds. The ipTM of 0.12 is particularly diagnostic: values below 0.5 in Boltz/AlphaFold-class models indicate that the predicted complex interface has no reliable geometry, and below 0.3 is effectively random. This collapse in confidence relative to Folds #22 and #66 (pLDDT 0.56 in both) almost certainly reflects a tool-limit failure. Dab is a non-proteinogenic amino acid not present in standard AlphaFold/Boltz training distributions, and the covalent crosslink it forms with Asp-10 creates a macrocyclic constraint that the model cannot represent with canonical atom types. The prediction effectively attempted to fold a structurally constrained peptide using a force field and learned representations that do not encode that constraint, producing an unphysical, low-confidence output.

The heuristic sequence-based profile (not derived from the 3D prediction) suggests low aggregation propensity (0.174), moderate stability (0.325), very low BBB penetration (0.075), and a long estimated half-life — consistent with what one would predict for a stapled peptide with reduced proteolytic accessibility. These are rough estimates only and should not be interpreted as validating the modification. The literature raises several genuine biological concerns beyond the tool limitation: the Leu-10→Asp substitution introduces a charged carboxylate into what is likely a hydrophobic interface region; the Dab substitution at position 14, while at a known mutable position (S14G is a gain-of-function variant), uses a non-natural residue with an extra amine that could disrupt native contacts; and Morris et al.'s fiber co-assembly data hint that conformational flexibility in HN may itself be

mechanistically important, meaning a rigidly locked analog might impair rather than sharpen BAX engagement.

The fold cannot be assessed as biologically failed. It was assessed as computationally intractable with the current toolset. The hypothesis — that a lactam staple would produce higher local pLDDT and interface confidence than disulfide staples — is scientifically reasonable and grounded in the well-established chemistry of lactam-based helix nucleators. Adjudicating it will require either force-field-based molecular dynamics (which can model crosslinked macrocycles with parameterized non-standard residues), experimental CD/NMR to confirm helicity of the synthesized peptide, or direct BAX binding measurements such as SPR or ITC.

RESEARCH BRIEF

FOLD №78 — HUMANIN S14DAB/ L10D LACTAM STAPLE — DISCARDED

> **Verdict: DISCARDED (tool-limit failure)** — Not biologically disproved. The structural prediction pipeline could not model the Dab non-canonical residue or the covalent lactam crosslink with sufficient confidence to yield interpretable results.

TLDR

FOLD №78 was DISCARDED due to a tool-limit failure. The intramolecular lactam bridge between Asp-10 and Dab-14 requires modeling a non-proteinogenic amino acid (L-2,4-diaminobutyric acid) and a covalent macrocyclic constraint that lies outside the training distribution and atom-type vocabulary of the Boltz-2/AlphaFold-class predictors used here. The resulting pLDDT of 0.44 and ipTM of 0.12 do not reflect the peptide's biological potential — they reflect the model's inability to encode the chemistry. This is a tool-limit discard, not a biological invalidation.

WHAT WE TRIED

Building on the two PROMISING Humanin disulfide-staple folds in this lab — Fold #22 (i,i+6 Cys-8/Cys-14, pLDDT 0.56) and Fold #66 (i,i+4 Cys-7/Cys-11, pLDDT 0.56) — this fold tested whether replacing the redox-sensitive disulfide staple with a chemically irreversible lactam bridge would sharpen the predicted helical geometry and BAX-interface confidence. The chemistry: native Leu-10 was replaced with L-Asp (to provide a β-carboxylate electrophile), and native Ser-14 was replaced with L-2,4-

diaminobutyric acid / Dab (to provide a γ-amine nucleophile). A covalent amide bond between these two side chains creates an i,i+4 macrocyclic lactam spanning exactly one helical turn — the textbook helix-nucleating geometry (Felix, Houston) and the same spacing used in published SAHB analogs of BH3 peptides targeting BCL-2 family grooves.

The scientific rationale was sound: a redox-stable amide bridge cannot be reduced by the cytosolic glutathione pool that would cleave a disulfide, making this staple more appropriate for the intracellular BAX target where Folds #22 and #66 would be vulnerable. Position 14 is known to tolerate modification — the S14G substitution (HNG) is a well-documented gain-of-function analog — and position 10 is predicted solvent-facing in helical models. The prediction target was that the 7–15 segment would achieve local pLDDT > 0.65 and that the interface ipTM would match or exceed the 0.56 baseline from the disulfide folds.

WHY IT WAS DISCARDED

The fold returned pLDDT 0.44, pTM 0.35, and ipTM 0.12 — a substantial degradation relative to the disulfide folds at all three metrics. The most likely cause is that **Dab is not a proteinogenic amino acid** and its γ-amine is not encodable as a canonical residue in Boltz-2's sequence vocabulary or scoring function. The covalent lactam crosslink further imposes a macrocyclic backbone constraint that the predictor cannot represent: it uses a standard open-chain atom graph. The model therefore attempts to fold the peptide as if the staple constraint does not exist, producing a physically incorrect, disordered ensemble and inflating positional uncertainty across the entire sequence. This is the same class of failure seen in Fold #59 (N-terminal myristoylation, FAILED), where a non-canonical chemical modification overwhelmed the predictor's representations.

By contrast, Folds #22 and #66 installed cysteine residues — canonical amino acids — and relied on the predictor's implicit treatment of disulfide bonds, which are encoded in training data. That approach yielded pLDDT 0.56 in both cases, sufficient for a PROMISING verdict. The lactam staple trades chemical stability for computational tractability.

An additional biological concern worth flagging: the Leu-10 → Asp substitution introduces a charged, hydrophilic side chain into what is likely a hydrophobic region of the HN–BAX interface. Even if the staple were correctly modeled, this substitution alone could disrupt native hydrophobic contacts with the BAX BH3-binding groove. The double modification (L10D + S14Dab) was necessary to install the staple but creates a compound perturbation that has not been evaluated.

WHAT THIS DOESN'T MEAN

DISCARDED is not "disproved." This fold was discarded because the current prediction pipeline lacks the atom-type vocabulary and covalent crosslink representation required to model a Dab-containing lactam-stapled peptide — not because the peptide was predicted to be inactive, misfolded, or non-binding. The scientific hypothesis (that an amide staple would confer greater helical stability and redox stability than the disulfide staples from Folds #22 and #66) is well-grounded in published chemistry and remains entirely open. The 0.44 pLDDT score is an artefact of tool mismatch, not a signal about the peptide's actual helical propensity or BAX affinity. Lactam-stapled α-helical peptides targeting BCL-2 family hydrophobic grooves have repeatedly shown enhanced binding affinity, proteolytic stability, and cellular activity in published literature — the concept is sound. What is missing is the right computational tool to evaluate this specific instance.

WHAT WOULD ANSWER THE QUESTION

- **Molecular dynamics / FEP with parameterized non-standard residues:** OpenMM or GROMACS with a custom GAFF2 or CHARMM CGenFF parameter set for Dab and the Asp–Dab lactam bond could model the covalent constraint explicitly and generate helicity, stability, and binding free energy predictions far more reliably than AlphaFold-class models for this chemistry. FEP+ (Schrödinger) supports macrocyclic peptides with non-canonical residues and would be the gold-standard computational approach.
- **Circular dichroism (CD) spectroscopy:** Synthesizing the peptide (Fmoc SPPS with Dab Fmoc protection and on-resin cyclization) and measuring helical content in buffer ± TFE would directly confirm whether the lactam staple enforces the expected α-helical conformation — a critical preliminary validation before any binding assay.
- **Surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC) with recombinant BAX:** Direct binding affinity measurement (K_D, ΔH, ΔS) against monomeric BAX protein would determine whether the stapled analog binds more tightly than native HN or the disulfide analogs. Guo et al. (2003) demonstrated that cell-free binding assays with isolated mitochondria are feasible and sensitive for HN/BAX interactions.
- **Cellular MOMP inhibition assay:** A cytochrome c release assay in a BAX-dependent apoptosis model (e.g., BAX/BAK double-knockout MEFs reconstituted with BAX) would determine whether the lactam-stapled analog retains or enhances functional anti-apoptotic activity relative to native HN and the S14G (HNG) benchmark, while also reporting on cell permeability of the stapled peptide.

RAW METRICS

Metric	Value	Interpretation
pLDDT	0.44	Very low — below interpretable threshold (< 0.50)
pTM	0.35	Low — global fold topology unreliable
ipTM	0.12	Very low — interface geometry not modeled (< 0.30 = effectively random)
Chai-1 agreement	None	Ensemble comparison unavailable
Boltz-2 affinity	No values	Module did not return output
Heuristic aggregation propensity	0.174	Low (sequence-based estimate only)
Heuristic stability score	0.325	Moderate (sequence-based estimate only)
Heuristic BBB penetration	0.075	Very low — not expected for a 24-mer with lactam
Heuristic half-life	Long (>6 h)	Consistent with reduced protease access from staple

Note: heuristic profile values are sequence-based estimates, not derived from the 3D prediction, and do not reflect the covalent lactam constraint.

SEQUENCES

NATIVE

```
MAPRGFSCLLLLTSEIDLPVKRRA
```

MODIFIED

```
MAPRGFSC-L-D-LL-Dab-EIDLPVKRRA (positions: M1 A2 P3 R4 G5 F6 S7 C8 L9 D10 L11 L12 T13 Dab14 E15 I16 D17 L18 P19 V20 K21 R22 R23 A24; lactam between Asp10-βCOOH and Dab14-γNH2)
```

CAVEATS

- in silico prediction only — requires wet lab validation
- single-run prediction (not ensembled)

- predicted properties may not reflect real-world biological behavior
- this is research, not medical advice
- DISCARDED verdict reflects tool-limit failure, not biological disproof — Dab is a non-proteinogenic amino acid not encodable in standard AlphaFold/Boltz residue vocabularies
- the covalent lactam crosslink between Asp-10 and Dab-14 cannot be represented as a canonical backbone constraint in current structure predictors — the pLDDT/ipTM scores are artefacts of this mismatch
- heuristic property estimates (aggregation, stability, BBB, half-life) are sequence-based calculations that do not account for the macrocyclic staple geometry or the Dab non-standard residue
- Leu-10 → Asp substitution introduces a charged residue into a potentially hydrophobic interface region — a biological concern independent of the tool limitation
- the HN–BAX complex has no published atomic-resolution structure; the binding epitope on HN is inferred, not directly mapped

CITATIONS

1. **PMID —** (2003) — — Humanin peptide suppresses apoptosis by interfering with Bax activation
2. **PMID —** (2019) — — Humanin induces conformational changes in the apoptosis regulator BAX and sequesters it into fibers, preventing mitochondrial outer-membrane permeabilization
3. **PMID —** (2005) — — Cytoprotective peptide humanin binds and inhibits proapoptotic Bcl-2/Bax family protein BimEL
4. **PMID —** (2004) — — Humanin: after the discovery
5. **PMID —** (2004) — — Unravelling the role of Humanin
6. **PMID —** (2021) — — Humanin: A mitochondrial-derived peptide in the treatment of apoptosis-related diseases
7. **PMID —** (2026) — — Renoprotective Effect of S14G-Humanin on Renal Ischemia/Reperfusion Injury by Activation of STAT3 and ERK 1/2 Signal Transduction Pathways in Rats
8. **PMID —** (2022) — — Humanin and Alzheimer's disease: The beginning of a new field
9. **PMID —** (2023) — — Humanin and Its Pathophysiological Roles in Aging: A Systematic Review
10. **PMID —** (2016) — — Humanin: Functional Interfaces with IGF-I

SOLANA SIGNATURE 3WTR9CS4e7Pk3LVxEHbayfJXDzbmUhfHGXA84c6ZqkcYemkwP9S7iKvv1wXH8gbFL7cdMDPWL3Y6e9xonSgQCB2a
DATA SHA-256 0e9aecf6a1defa00dfadb7a2d06a7585dfdc1681a1fccabae888aa2388c7b4ac
VERIFY https://solscan.io/tx/3WTR9CS4e7Pk3LVxEHbayfJXDzbmUhfHGXA84c6ZqkcYemkwP9S7iKvv1wXH8gbFL7cdMDPWL3Y6e9xonSgQCB2a